$9.71 $0.25 (2.6%)

04:00 PM EST on 11/22/19

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 5 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Current Price $9.71 Mkt Cap $2.4B
Open $9.50 P/E Ratio 0.00
Prev. Close $9.46 Div. (Yield) $0.00 (0.0%)
Daily Range $9.45 - $9.75 Volume 1,726,870
52-Wk Range $7.11 - $14.62 Avg. Daily Vol. 3,517,146

Caps

How do you think NASDAQ:FOLD will perform against the market?

Add Stock to CAPS Watchlist

All Players

99 Outperform
21 Underperform
 

All-Star Players

18 Outperform
4 Underperform
 

Wall Street

5 Outperform
3 Underperform
 

Top NASDAQ:FOLD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

colbydrf (< 20)
Submitted September 25, 2014

It has been doing well, and it may represent a market niche. It is worth tracking, at least.

zzlangerhans (99.78)
Submitted December 03, 2012

Amicus is showing another upward kick in advance of data from Study 011 of Amigal in Fabry's disease, with topline results likely to be released this month. Similar upward movements earlier this year have not been sustained. I've been dubious about… More

Recent Community Commentary

Read the most recent pitches from players about FOLD.

Recs

0
Member Avatar Speedylove (< 20) Submitted: 1/27/2016 4:46:27 PM : Outperform Start Price: $5.93 NASDAQ:FOLD Score: -0.08

New treatment for Fabreze

Recs

1
Member Avatar colbydrf (< 20) Submitted: 9/25/2014 5:43:21 PM : Outperform Start Price: $6.26 NASDAQ:FOLD Score: -2.99

It has been doing well, and it may represent a market niche. It is worth tracking, at least.

Recs

0
Member Avatar asilverp (27.08) Submitted: 8/29/2014 9:17:32 AM : Underperform Start Price: $7.35 NASDAQ:FOLD Score: +23.03

Very high valuations + limited growth. They make drugs for orphan diseases. Unless they cure Parkinson's disease, we are looking at a terrible stock. Really noble kind of company though, if the valuations were (much) better, I would buy it. Good niche operation.

Leaderboard

Find the members with the highest scoring picks in FOLD.

Score Leader

dcsilver

dcsilver (< 20) Score: +599.88

The Score Leader is the player with the highest score across all their picks in FOLD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille2 98.78 4/16/2014 10/31/2019 Outperform 5Y $1.83 +432.05% +67.38% +364.67 0 Comment
portefeuille12 29.24 4/25/2014 Outperform 5Y $1.84 +427.72% +66.61% +361.11 0 Comment
portefeuille 98.35 4/4/2014 Outperform 5Y $2.06 +371.36% +66.19% +305.17 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. peregrine 96.81 4/7/2014 Outperform 5Y $2.11 +360.19% +68.60% +291.59 0 Comment
portefeuille6 99.36 4/11/2014 6/10/2014 Outperform 3W $2.12 +358.02% +71.33% +286.69 0 Comment
edj1989 32.46 12/20/2013 Outperform 1Y $2.13 +355.87% +72.13% +283.74 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 70.79 5/22/2014 Outperform 5Y $2.21 +339.37% +63.93% +275.43 0 Comment
qubit15 23.72 1/21/2009 Underperform NS $7.91 +22.76% +288.55% +265.80 0 Comment
isusan < 20 6/25/2013 Outperform 5Y $2.11 +361.28% +96.15% +265.14 0 Comment
anticitradeshort 31.35 4/20/2009 Underperform NS $8.75 +10.97% +267.34% +256.36 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for FOLD.